BPC-157 + TB-500 Oral Blend: Scientific Profile
Publicado el · Actualizado el
Research compound: Oral blend of the peptides BPC-157 and TB-500. BPC-157 modulates angiogenesis pathways, while TB-500 promotes cell differentiation and tissue remodeling in preclinical models.
The BPC-157 + TB-500 Oral Blend compound represents a synergistic formulation designed for biotechnological research focused on systemic tissue regeneration and the modulation of inflammatory processes. BPC-157 (Body Protection Compound) is a pentadecapeptide derived from gastric juices that has demonstrated intrinsic gastric stability, which allows its study in an oral vial for the evaluation of intestinal mucosa integrity and the repair of tendons and ligaments through the upregulation of fibroblast growth factor receptors.
On the other hand, TB-500 is a synthetic version of the active domain of Thymosin Beta-4, a protein essential in the regulation of G-actin. In research models, this peptide facilitates cellular chemotaxis and vasculogenesis, enabling the migration of progenitor cells toward sites of biological injury. The oral combination takes advantage of BPC-157's enzymatic resistance to act as a carrier or adjuvant in tissue absorption and signaling.
Studies suggest that this mixture potentiates the expression of nitric oxide synthase and the organization of type I collagen, processes fundamental to the homeostasis of the locomotor system. Its application in the laboratory environment focuses on the observation of the speed of post-traumatic recovery in soft tissues and the resolution of experimental pathologies in the gastrointestinal tract.
Mechanism of action
BPC-157 acts through the activation of the VEGFR2 signaling pathway and the modulation of collagen synthesis, promoting adaptive angiogenesis. TB-500 (Thymosin Beta-4) binds to monomeric actin, preventing its polymerization and allowing greater cell mobility. Together, they induce an upregulation of endogenous growth factors and a reduction of proinflammatory cytokines at the research site.
Mechanism summary
Synergy of growth-factor receptor modulation and actin regulation to promote cell migration and angiogenesis in damaged tissues.
Clinical Studies (6)
There is no peer-reviewed literature on BPC-157 + TB-500 Oral Blend as a combination. What follows is the literature for each component separately:
- About BPC-157: Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats (Xue, et al. · World Journal of Gastroenterology · 2004) PMID 15052688.
- About TB-500: Thymosin beta4 accelerates wound healing (Malinda, et al. · Journal of Investigative Dermatology · 1999) PMID 10469335.
- About BPC-157: Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157 (Sikiric, et al. · Current Medicinal Chemistry · 2012) PMID 22300085.
- About TB-500: Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications (Goldstein, et al. · Expert Opinion on Biological Therapy · 2012) PMID 22074294.
- About BPC-157: The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (Chang, et al. · Journal of Applied Physiology · 2011) PMID 21030672.
- About TB-500: Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury (Sosne, et al. · Experimental Eye Research · 2002) PMID 11950239.
Warnings
BPC-157 + TB-500 Oral Blend is a research-use-only (RUO) compound; the following warnings and handling considerations apply to its laboratory use:
- For laboratory research purposes only
- Keep out of reach of untrained personnel
- Verify packaging integrity before reconstitution
- Models with documented active neoplasms
- Known hypersensitivity to peptide sequences
- Research involving severe immunosuppression
- Pregnancy or lactation in study subjects
Technical data
- CAS
- 137525-51-0 / 77591-33-4
- Molecular formula
- C62H98N16O22 (BPC) | C212H350N56O78S (TB)
- Molecular weight
- 1419.5 Da
- Compound type
- blend
- Storage
- 15-25°C lyophilized (cool, dry environment)
- Shelf life (lyophilized)
- 24 months
- Shelf life (reconstituted)
- 7-14 days refrigerated once dissolved
- Light-sensitive
- No
Available for research
BPC-157 + TB-500 Oral Blend is available as a research reagent (RUO):
Frequently asked questions about BPC-157 + TB-500 Oral Blend
What is BPC-157 + TB-500 Oral Blend?
Research compound: Oral blend of the peptides BPC-157 and TB-500. BPC-157 modulates angiogenesis pathways, while TB-500 promotes cell differentiation and tissue remodeling in preclinical models.
What is the mechanism of action of BPC-157 + TB-500 Oral Blend?
Synergy of growth-factor receptor modulation and actin regulation to promote cell migration and angiogenesis in damaged tissues.
What is BPC-157 + TB-500 Oral Blend researched for?
In preclinical research, BPC-157 + TB-500 Oral Blend is studied mainly in: Research on the repair of extracellular matrix; Modulation of the systemic inflammatory response; Study of angiogenesis in hypoxic tissues. Material exclusively for scientific research.
What are the chemical properties of BPC-157 + TB-500 Oral Blend?
Molecular weight 1419.5 Da; CAS number 137525-51-0 / 77591-33-4.
How is BPC-157 + TB-500 Oral Blend stored?
Storage conditions: 15-25°C lyophilized (cool, dry environment); lyophilized stability: 24 months; once reconstituted: 7-14 days refrigerated if dissolved.
What administration routes are studied for BPC-157 + TB-500 Oral Blend?
In research models the following are described: Oral (Gavage or dissolution). Use is exclusively for scientific research.